Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025

10 Sep 2025 08:00 CEST

Oslo, Norway, 10 September 2025 - Zelluna (OSE: ZLNA), a company pioneering
allogeneic 'off the shelf' T Cell Receptor based Natural Killer (TCR-NK) cells
for the treatment of cancer, announces an Investor Science and Strategy Forum to
be held in Oslo on Wednesday 17 September 2025 at 11:30am CET.

Attendance by registration only.

The format will be a panel discussion and open questions and answers (Q&A).

The panel will include:

Dr. Namir Hassan, CEO, Zelluna ASA, Moderator

Prof. Bent Jakobsen, Pioneer of T Cell Receptor (TCR) therapy for cancer; former
founder of two public TCR based companies including Immunocore. Zelluna ASA
Board Member.

Prof Fiona Thistlethwaite, Medical Oncology Consultant within the Experimental
Cancer Medicines Team (ECMT), Clinical Lead for the Advanced Immunotherapy and
Cell Therapy (AICT) Team, The Christie, UK

Details of the event are as follows:

Date: Wednesday 17 September 2025.

Time: 11:30 - 13:00 CET, Lunch served.

Venue: Meeting Room 4, Hotel Continental, Stortingsgata 24/26, Oslo.

Format: Panel discussion and open Q&A 12:00 - 13:00 CET.

Attendance is by registration only and spaces are limited.

Please confirm your registration by Monday 15 September 2025 by email to:

Hans Vassgård Eid, CFO, Zelluna ASA on: hans.eid@zelluna.com
(mailto:hans.eid@zelluna.com)

For further information, please contact:

Namir Hassan, CEO, Zelluna ASA

Email: namir.hassan@zelluna.com (mailto:namir.hassan@zelluna.com)

Phone: +44 7720 687608

Hans Vassgård Eid, CFO, Zelluna ASA

Email: hans.eid@zelluna.com (mailto:[%20hans.eid@zelluna.com])

Phone: +47 482 48632

About Zelluna ASA

Zelluna's mission is to deliver transformative treatments with the capacity to
cure advanced solid cancers, in a safe and cost-efficient manner, to patients on
a global scale. The Company aims to do this by combining the most powerful
elements of the immune system through pioneering the development of "off the
shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).
The TCR-NK platform offers a unique mechanism of action with broad cancer
detection capability to overcome the diversity of tumours and will be used "off
the shelf" to overcome scaling limitations of current cell therapies. The lead
program is a world's first MAGE-A4 targeting "off the shelf" TCR-NK for the
treatment of various solid cancers; a pipeline of earlier products follows. The
Company is led by a management team of biotech entrepreneurs with deep
experience in discovery through to clinical development of TCR and cell-based
therapies including marketed products.

For more information, please visit www.zelluna.com
(https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.zelluna.co
m%2F&data=05%7C02%7Cnamir.hassan%40zelluna.com%7Ced8cddea86b14997fdfe08dd7dca316
c%7Ccede8a9004b24ee9b76f4516596ada0e%7C0%7C0%7C638805029541430284%7CUnknown%7CTW
FpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTW
FpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=9pTn8Iupu8%2FABSEmbfBxpII6MF1KmK%2BJj8
k3MozVlII%3D&reserved=0)

More information:
Access the news on Oslo Bors NewsWeb site